In second line with advanced or recurrent biliary tract cancer refractory to first line gemcitabine plus cisplatin,efficacy of mFOLFOX/FOLFIRI vs mFOLFOX will be evaluated at randomized phase 2 trial.
Age ≥ 19 years.
Diagnosed with biliary tract cancer, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer.
Either unresectable advanced disease or recurrence after curative surgery.
ECOG (Eastern Cooperative Oncology Group) performance status of 0-2
Patients with prior exposure to oxaliplatin or irinotecan in previous cancer treatments.
Patients with metastatic or unresectable biliary tract cancer who have received second- line or higher chemotherapy.
Pregnant or breastfeeding women.
Patients with a history of other malignancies within the past 3 years, except for papillary or follicular thyroid cancer.